Sun Pharma Q1 Review - Dolat Capital Maintains 'Reduce', Sees Current Valuations To Limit Upside

Wait 5 sec.

With limited upside from current levels, Dolat Capital maintains 'Reduce' rating, with a revised target price of Rs 1,696 at 30x FY27E P/E.